MY191875A - Solid dosage form - Google Patents
Solid dosage formInfo
- Publication number
- MY191875A MY191875A MYPI2015000938A MYPI2015000938A MY191875A MY 191875 A MY191875 A MY 191875A MY PI2015000938 A MYPI2015000938 A MY PI2015000938A MY PI2015000938 A MYPI2015000938 A MY PI2015000938A MY 191875 A MY191875 A MY 191875A
- Authority
- MY
- Malaysia
- Prior art keywords
- dosage form
- solid dosage
- active material
- biologically active
- oral cavity
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Emergency Medicine (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
There is provided a solid dosage form adapted for the release of a biologically active material in the oral cavity wherein the dosage form comprises at least one biologically active material, and at least one matrix forming agent, wherein the dosage form substantially dissolves in the oral cavity. A method of producing the same and a kit comprising the same are also provided.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2012238330A AU2012238330B1 (en) | 2010-10-26 | 2012-10-11 | Fast Dissolving Solid Dosage Form |
AU2013200682A AU2013200682C1 (en) | 2010-10-26 | 2013-02-08 | Fast Dissolving Solid Dosage Form |
AU2013200684A AU2013200684B1 (en) | 2010-10-26 | 2013-02-08 | Fast Dissolving Solid Dosage Form |
PCT/IB2013/002594 WO2014057351A1 (en) | 2012-10-11 | 2013-10-11 | Solid dosage form |
Publications (1)
Publication Number | Publication Date |
---|---|
MY191875A true MY191875A (en) | 2022-07-18 |
Family
ID=50478109
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MYPI2015000938A MY191875A (en) | 2012-10-11 | 2013-10-11 | Solid dosage form |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP2906201A4 (en) |
JP (1) | JP2015533155A (en) |
KR (1) | KR20150063567A (en) |
CN (2) | CN104812378B (en) |
CA (1) | CA2886573C (en) |
HK (1) | HK1208353A1 (en) |
IL (2) | IL238104B (en) |
MY (1) | MY191875A (en) |
NZ (1) | NZ706302A (en) |
SG (1) | SG11201502425WA (en) |
WO (1) | WO2014057351A1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6217052B2 (en) * | 2016-04-21 | 2017-10-25 | 邦赫 小牧 | Effervescent tablet for oral cleaning |
CN109310646A (en) | 2016-05-05 | 2019-02-05 | 阿奎斯蒂弗医疗股份有限公司 | Enhance the adrenaline composition of delivering |
JP2017193547A (en) * | 2017-05-08 | 2017-10-26 | 邦赫 小牧 | Foaming tablet for oral cleaning |
KR20200060748A (en) * | 2017-09-27 | 2020-06-01 | 어퀘스티브 테라퓨틱스, 아이엔씨. | Enhanced delivery ephnephrine and prodrug compositions |
IT201800003507A1 (en) * | 2018-03-13 | 2019-09-13 | Fulton Medicinali S P A | SUBLINGUAL TABLET INCLUDING SILDENAFIL CITRATE |
JP2022516361A (en) * | 2019-01-07 | 2022-02-25 | アンテシップ バイオベンチャーズ トゥー エルエルシー | A combination of dextromethorphan and bupropion for the treatment of depression |
CN109846841B (en) * | 2019-01-18 | 2021-06-01 | 西安力邦医药科技有限责任公司 | Quick-acting clobazam oral freeze-dried preparation and preparation method thereof |
US20220062200A1 (en) * | 2019-05-07 | 2022-03-03 | Clexio Biosciences Ltd. | Abuse-deterrent dosage forms containing esketamine |
US11382873B1 (en) * | 2021-01-08 | 2022-07-12 | Vitalis Analgesics LLC | Oral administration of ketamine |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6596298B2 (en) * | 1998-09-25 | 2003-07-22 | Warner-Lambert Company | Fast dissolving orally comsumable films |
US6552024B1 (en) * | 1999-01-21 | 2003-04-22 | Lavipharm Laboratories Inc. | Compositions and methods for mucosal delivery |
CA2417736A1 (en) * | 2000-07-19 | 2002-01-24 | Lavipharm Laboratories, Inc. | Sildenafil citrate solid dispersions having high water solubility |
US7118765B2 (en) * | 2001-12-17 | 2006-10-10 | Spi Pharma, Inc. | Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms |
RU2342953C2 (en) * | 2003-02-24 | 2009-01-10 | Фармасьютикал Продакшенз, Инк. | Transmucosal system of delivery of medical products |
JP2008546786A (en) * | 2005-06-23 | 2008-12-25 | シェーリング コーポレイション | Rapidly absorbable oral formulation of PDE5 inhibitor |
KR100905027B1 (en) * | 2007-10-03 | 2009-06-30 | (주)씨엘팜 | Edible Film |
WO2009045022A2 (en) * | 2007-10-03 | 2009-04-09 | C.L. Pharm | Edible film |
DE102008014533A1 (en) * | 2008-03-15 | 2009-09-17 | Lts Lohmann Therapie-Systeme Ag | Gingival wafer |
US8623401B2 (en) * | 2008-03-27 | 2014-01-07 | Fenwafe Inc. | Wafer formulation |
US8715715B2 (en) * | 2008-11-03 | 2014-05-06 | Nal Pharmaceuticals Ltd. | Dosage form for insertion into the mouth |
PL3254676T3 (en) * | 2009-10-30 | 2019-06-28 | Ix Biopharma Ltd | Fast dissolving solid dosage form |
CN103025321A (en) * | 2010-03-23 | 2013-04-03 | 生物联合制药公司 | Fast dissolving drug delivery systems |
FR2967066B1 (en) * | 2010-11-04 | 2013-06-14 | Ethypharm Sa | SUBLINGUAL USE OF NON-COMPRESSED MICROGRANULES |
JP5841433B2 (en) * | 2012-01-11 | 2016-01-13 | 日東電工株式会社 | Intraoral film-form base and preparation |
JP6572201B2 (en) * | 2013-03-15 | 2019-09-04 | エアーピオ セラピューティクス インコーポレイテッド | Compositions, formulations and methods for treating ocular diseases |
-
2013
- 2013-10-11 MY MYPI2015000938A patent/MY191875A/en unknown
- 2013-10-11 WO PCT/IB2013/002594 patent/WO2014057351A1/en active Application Filing
- 2013-10-11 CA CA2886573A patent/CA2886573C/en active Active
- 2013-10-11 NZ NZ706302A patent/NZ706302A/en unknown
- 2013-10-11 EP EP13845400.4A patent/EP2906201A4/en not_active Withdrawn
- 2013-10-11 CN CN201380060281.3A patent/CN104812378B/en active Active
- 2013-10-11 KR KR1020157012031A patent/KR20150063567A/en not_active Application Discontinuation
- 2013-10-11 CN CN201711156600.7A patent/CN107669649A/en active Pending
- 2013-10-11 SG SG11201502425WA patent/SG11201502425WA/en unknown
- 2013-10-11 JP JP2015536236A patent/JP2015533155A/en active Pending
-
2015
- 2015-04-01 IL IL238104A patent/IL238104B/en active IP Right Grant
- 2015-09-15 HK HK15108989.9A patent/HK1208353A1/en unknown
-
2020
- 2020-03-04 IL IL273076A patent/IL273076A/en unknown
Also Published As
Publication number | Publication date |
---|---|
HK1208353A1 (en) | 2016-03-04 |
KR20150063567A (en) | 2015-06-09 |
WO2014057351A1 (en) | 2014-04-17 |
IL238104B (en) | 2020-03-31 |
NZ706302A (en) | 2017-07-28 |
IL273076A (en) | 2020-04-30 |
CN104812378B (en) | 2017-12-01 |
IL238104A0 (en) | 2015-05-31 |
EP2906201A4 (en) | 2016-10-19 |
JP2015533155A (en) | 2015-11-19 |
CA2886573C (en) | 2019-04-02 |
EP2906201A1 (en) | 2015-08-19 |
CA2886573A1 (en) | 2014-04-17 |
CN107669649A (en) | 2018-02-09 |
SG11201502425WA (en) | 2015-05-28 |
CN104812378A (en) | 2015-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY150626A (en) | Fast dissolving solid dosage form | |
MY191875A (en) | Solid dosage form | |
MX2015017036A (en) | Method for producing renal precursor cells, and drug containing renal precursor cells. | |
MX2013008850A (en) | Compositions and methods for treating cardiovascular diseases. | |
EP2279227A4 (en) | Anionic latex as a carrier for active ingredients and methods for making and using the same | |
MX354137B (en) | Topical minocycline compositions and methods of using the same. | |
CA141113S (en) | Dispenser for pharmaceutical powder formulations | |
JO3052B1 (en) | Dividable galenical form allowing modified release of the active ingredient | |
MY162411A (en) | Crystalline forms of a macrolide, and uses therefor | |
MX356210B (en) | Acrylic polymer formulations. | |
PE20140255A1 (en) | DISPERSIBLE TABLET IN ORAL FORM | |
DOP2012000170A (en) | PROCESS FOR THE MANUFACTURE OF AN ACTIVE PHARMACEUTICALLY AGENT | |
EP2844185B8 (en) | Method for producing dentures and articulator for carrying out the method | |
PH12014502834B1 (en) | Pharmaceutical form for extended release of active substances | |
MY162688A (en) | Oral care compositions | |
MX2013003160A (en) | Antidiabetic solid pharmaceutical compositions. | |
MX349563B (en) | Pharmaceutical formulation of nanonised fenofibrate. | |
MY197131A (en) | Fast dissolving solid dosage form | |
EP2586523A4 (en) | Process for producing emulsifier-producing material, process for producing emulsifier, emulsifier for orally administered composition, and orally administered composition | |
MX2013012551A (en) | Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease. | |
CA142814S (en) | Medical patch | |
AU340340S (en) | A mold for pastries | |
AU340341S (en) | A mold for pastries | |
CA145654S (en) | Building block for a toy building set | |
CA145657S (en) | Building block for a toy building set |